Targeting the PI3K pathway in cancer: are we making headway?

@article{Janku2018TargetingTP,
  title={Targeting the PI3K pathway in cancer: are we making headway?},
  author={Filip Janku and Timothy A Yap and Funda Meric-Bernstam},
  journal={Nature Reviews Clinical Oncology},
  year={2018},
  volume={15},
  pages={273-291}
}
The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated pathways in cancer and, consequently, more than 40 compounds that target key components of this signalling network have been tested in clinical trials involving patients with a range of different cancers. The clinical development of many of these agents, however, has not advanced to late-phase randomized trials, and the antitumour activity of those that have been evaluated in comparative prospective studies has typically been… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 88 times over the past 90 days. VIEW TWEETS
6 Citations
143 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 143 references

A phase 1 open‐label study to identify a dosing regimen of the pan‐AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA‐mutated breast and gynecologic cancers

  • U Banerji
  • Clin. Cancer Res
  • 2017

Similar Papers

Loading similar papers…